




ThermoFisher
S C I E N T I F I C

NEW on Thermo Scientific™ Orbitrap Fusion™ Lumos™
Tribrid™ MS


Stephane Houel, Ph.D.
BioPharma Vertical Marketing

The world leader in serving science


NEW On Thermo Scientific Orbitrap Fusion Lumos MS in 2017



Challenges In Life Science Mass Spectrometry



Complex samples,
insufficient depth of
analysis



Isobaric analytes,
confirmation of
elemental
composition



Comprehensive
sequence
characterization of
protein drugs




Structural elucidation
of lipids, metabolites,
xenobiotics and others

**Thermo Scientific™
Orbitrap Fusion™ Lumos™ Tribrid™
Mass Spectrometer is the most
sensitive and versatile MS system**



NEW On Thermo Scientific Orbitrap Fusion Lumos MS in 2017






Challenge

Achieving maximal depth of analysis in complex samples

- MS spectra are complex
- Fast & sensitive instrumentation run out of data-dependent targets
- Can we determine more unique peaks for MS/MS analysis?


Typically, MS/MS rate in a DDA experiment is well below its maximum




Senko et al., 2013

Advanced Peak Determination: *Reading Between The Lines*

STANDARD PEAK DETERMINATION



ADVANCED PEAK DETERMINATION




Details

- Advanced Peak Determination (APD) algorithm identifies the **charge states and monoisotopic m/z** values of isotopic envelopes at greatly improved peak depths **in real-time**
- This significantly increases the population of precursors available for data-dependent analysis, which in turn results in more MS^n spectra, PSMs, and unique peptide identifications
- APD has been evaluated for peptides/proteins only. Improvements for small molecule analysis are still under investigation



APD Leads To Increased Number Of IDs In Proteomics Analyses

NEW DEPTHS OF ANALYSIS OF COMPLEX PROTEOMICS SAMPLES




APD Performance On A Tribrid

- APD leverages the low detection limits of the FTMS, and the incredibly high ion trap MS/MS spectral acquisition rate, to significantly boost the rate of unique peptide identifications during data-dependent LC-MS/MS
- We analyzed 1 μg of a HeLa digest by data-dependent LC-MS/MS
- Results that used to take 2 hours can be obtained in 1 hour
- Expected improvements for 1 μg HeLa standard (Pierce)*:
 - >25% unique peptide level
 - >5% protein level

*2 h gradient, OT MS at 240K FWHM, LT MS/MS, 20 ms max IT

APD Leads To Increased Number Of IDs In Proteomics Analyses

NEW DEPTHS OF ANALYSIS OF COMPLEX PROTEOMICS SAMPLES




APD Performance On A Tribrid

- APD leverages the low detection limits of the FTMS, and the incredibly high ion trap MS/MS spectral acquisition rate, to significantly boost the rate of unique peptide identifications during data-dependent LC-MS/MS
- We analyzed 1 μg of a HeLa digest by data-dependent LC-MS/MS
- Results that used to take 2 hours can be obtained in 1 hour
- Expected improvements for 1 μg HeLa standard (Pierce)*:
 - >25% unique peptide level
 - >5% protein level

*2 h gradient, OT MS at 240K FWHM, LT MS/MS, 20 ms max IT

APD Leads To Increased Number Of IDs In Proteomics Analyses

NEW DEPTHS OF ANALYSIS OF COMPLEX PROTEOMICS SAMPLES




APD Performance On A Tribrid

- APD leverages the low detection limits of the FTMS, and the incredibly high ion trap MS/MS spectral acquisition rate, to significantly boost the rate of unique peptide identifications during data-dependent LC-MS/MS
- We analyzed 1 μ g of a HeLa digest by data-dependent LC-MS/MS
- Results that used to take 2 hours can be obtained in 1 hour
- Expected improvements for 1 μ g HeLa standard (Pierce)*:
 - >25% unique peptide level
 - >5% protein level

*2 h gradient, OT MS at 240K FWHM, LT MS/MS, 20 ms max IT

Intact Protein Analysis With APD



On-the-fly charge state assignment of isotopically unresolved charge states of carbonic anhydrase

Charge Assignment Of Unresolved Charge States

- We analyzed the Thermo Scientific™ Pierce™ Intact Protein Standard Mix with a data-dependent LC-MS/MS method
- FTMS1 spectra were collected at 15k resolving power, and were the sum of 5 microscans
- With APD *on*, the instrument can accurately identify highly charged and complex protein envelopes on-the-fly
- It is now possible to execute more advanced top-down experiments including, **MS/MS fragmentation of one charge state per precursor**

Advanced Peak Determination Benefits Bottom Up and Top Down Proteomics

BOTTOM UP PROTEOMICS

Data-dependent experiments with complex peptide mixtures

TOP DOWN PROTEOMICS

Identification and characterization of intact proteins by MS



Turn APD On And Off In The Method Editor

The screenshot displays the 'Method Editor' software interface. At the top, there are three tabs: 'Global Parameters' (selected), 'Scan Parameters', and 'Summary'. Below the tabs is a 'Method Timeline' section with a horizontal axis showing time points: 23.3, 46.7, 70, 93.3, 116.7, and 140. A blue bar represents the method duration, which is set to 140 minutes. To the right of the timeline are buttons for 'New', 'Delete', and 'Clear', along with search and zoom controls.

The main area is divided into two sections: 'Global Parameters' and 'MS Properties'. The 'Global Parameters' section contains a graph with a vertical axis ranging from -2 (KV) to 2 (KV) and a horizontal axis with the same time points as the timeline. A red line is plotted on the graph. Below the graph is a section labeled 'MS' with a globe icon.

The 'MS Properties' section on the right contains the following settings:

- Application Mode: Standard
- Advanced Peak Determination: (highlighted with a red box)
- Default Charge State: 2
- Internal Mass Calibration:


Advanced Peak Determination is an optional Global MS property of the Method Editor.




The new APD algorithm provides new peptide precursors to go after and amounts to a 25-35% identification bonus. I have no doubt this will be a key technology in achieving deeper coverage and higher throughput for proteome analyses.




NEW On Thermo Scientific Orbitrap Fusion Lumos MS in 2017



Matching
C-trap



1M Orbitrap



A Kit Comprising An Orbitrap And A C-trap Assembly

- Ultra high resolution (1,000,000 at m/z 200, 2 sec transient) while maintaining isotope ratio specs
- A matching C-trap and a high-performance Thermo Scientific™ Orbitrap™ mass analyzer, available for factory installations or field upgrades




1M option for peptide mapping: Do we need it?



Question

Does the lack of resolution prevent the detection/quantitation of almost isobaric components.

NISTmAb Digest Peptide Map




NISTmAb Digest Peptide Map Chromatogram

After processing in Thermo Scientific™ BioPharma Finder™ Software
GFYPSDIAVEWESNGQPENNYK




NL:
3.12E9
TIC MS
MAM_240K

RT: 0.00 - 70.52



Retention time of GFYPSDIAVEWESNGQPENNYK Peptides



GFYPSDIAVEWESNGQPENNYK (+2) m/z			
	Native	Deamidated	
M	1272.5693		
M+1	1273.0708	1273.0613	M
M+2	1273.5722	1273.5628	M+1
M+3	1274.0735	1274.0642	M+2
		1274.5656	M+3


→ $\Delta m/z = 0.0095$

GFYPSDIAVEWESNGQPENN[Deam]YK


Spectrum at the Apex of the Deamidated PENNYK Peptide

Isotopic Pattern Vs. Resolution

MAM-1000-011055-RT: 39.384 AV: 1 NL: 14925
 T: FTMS # pESI Full ms [300.0000-1800.0000]




GFYPSDIAVEWESNGQPENNYK (+2) m/z			
	Native	Deamidated	
M	1272.5693		
M+1	1273.0708	1273.0613	M
M+2	1273.5722	1273.5628	M+1
M+3	1274.0735	1274.0642	M+2
		1274.5656	M+3




PENN[Deam]YK Monoisotopic Peak vs. Resolution

MAM_200R#28035RT39034AV1 1INL2.0275
T: FTMS + p ESI Full ms [300.0000-1800.0000]



PENN[Deam]YK (+2 and+3): XIC of First 3 Isotopic Peaks for Quantitation



No.	Injection Name	Area counts*min GFYPSDIAVEWESNGQPENNYK [IsoDeamid]	Area counts*min GFYPSDIAVEWESNGQPEN[Deamid]NYK	Area counts*min GFYPSDIAVEWESNGQPENNYK	Relative Abundance % PENNYK-IsoDeam	Relative Aundance % PENNYK Deam
1	MAM_1M_Re	1.53E+05	9.71E+05	7.09E+07	0.212	1.348
2	MAM_500K	2.53E+05	1.61E+06	1.14E+08	0.219	1.396
3	MAM_240K	2.93E+05	1.93E+06	1.41E+08	0.204	1.342
4	MAM_120K	6.70E+05	3.48E+06	1.67E+08	0.391	2.028

Native
peptide


NISTmAb Digest Peptide Map Chromatogram

RT: 0.00 - 70.52

After processing in Thermo Scientific™ BioPharma Finder™ Software
VDNALQSGNSQESVTEQDSK




NL:
3.12E9
TIC MS
MAM_240K



VDNALQSGN[Deam]SQESVTEQDSK Monoisotopic Peak

MAM_200K#5893 RRT: 10.021 AM: 11 NOV 9 13:23:55
 T: FTMS +p ESI Full ms [300.0000-1800.0000]



Summary

- 1M Resolution can spectrally baseline resolve PENNYK deamidation from the native peptide for both +2 and +3 with <1 ppm mass accuracy
- Higher resolutions can benefit quantitation by preventing over integration of coeluting native+deamidated isotopes
- 1M resolution enables the detection of low level peptides obscured beneath their coeluting native counterparts

1M Ultra-High Resolution For Lipid Flux Analysis

UT Southwestern
Medical Center



“

The 1 million resolution Orbitrap is a unique tool to allow fluxomics analysis of lipids with sensitivity comparable to radioactivity tracing.

”

Matt Mitsche, The University of Texas


To know more, please watch recorded webinar on c&en WEBINARS website:

https://cen.acs.org/media/webinar/thermo_090717.html

c&en | WEBINARS

Let's Chew the Fat with Orbitrap MS - Enabling Lipid Metabolic Flux Studies and Structural Elucidation of Lipids with Ultra High Resolution and UVPD Fragmentation

NEW On Thermo Scientific Orbitrap Fusion Lumos MS in 2017





Challenge

Dissociation techniques currently available (CID, HCD and ETD) can be insufficient for comprehensive characterization of analytes of interest



UV Photodissociation (UVPD) option

- Provides unique fragments vs. other dissociations increasing sequence coverage of proteins
- Available only on Thermo Scientific™ Orbitrap Fusion™ Lumos™ MS

UVPD Implementation (Class 1 Laser System)



UVPD Source

The UVPD MSⁿ fragments are generated in the linear ion trap and can be detected by either the ion trap or Orbitrap


Compact Footprint

- UVPD source is embedded inside the instrument, directly connected to the dual-pressure linear ion trap
- UVPD source employs a 213 nm laser with 2.5 kHz repetition rate delivering >1.2 $\mu\text{J}/\text{pulse}$
- UVPD is a field upgradable option





UVPD Is Unique to the Thermo Scientific Orbitrap Fusion Lumos MS

Data Dependent Experiment: OTMS>UVPD OTMS²



UVPD Is Easy To Use



UVPD activation time is *m/z* independent:
The highest coverage is achieved at the same
activation time (17 ms) for two different charges
states of apomyoglobin

Data-Dependent MS ⁿ Scan Properties	
Isolation Mode	Quadrupole
Isolation Window (m/z)	1.6
Isolation Offset	Off
Activation Type	UVPD
Use Calibrated Molecular Weight-Dependent UVPD Activation Time	<input type="checkbox"/>
UVPD Activation Time (ms)	10
Detector Type	Orbitrap
Scan Range Mode	Auto: m/z Normal
Orbitrap Resolution	60000
AGC Target	2.0e5
Inject Ions for All Available Parallelizable Time	<input type="checkbox"/>
Maximum Injection Time (ms)	118
Microscans	1
Data Type	Profile
Use EASY-IC™	<input type="checkbox"/>
Scan Description	

User-Friendly Implementation

- The UVPD source is embedded inside the mass spectrometer for optimal performance and reliability
- Minimal set-up required by user
- User defined UVPD activation time (ms)
- Calibrated Molecular Weight-Dependent Activation Time
 - UVPD Activation time multiplier (%)



```
N Q V Q L Q Q P G A E L V K P G A S V K M S C K A S 25
26 G Y T F T S Y N M H W V K Q T P G R G L E W I G A 50
51 I Y P G N G D T S Y N Q K F K G K A T L T A D K S 75
76 S S T A Y M Q L S S L T S E D S A V Y Y C A R I S T 100
101 Y Y G G D W Y F N V W G A G T T V T V I S A A S T K 125
126 G P S V F P L A P S S K S T S G G T A A L G C L V 150
151 K D Y F P E P V T V S W N S G A L T S G V H T F P 175
176 A V L Q S S G L Y S L S S V V T V P S S L G T Q 200
201 T Y I C N V N H K P S N T K V D K K A E P K S C D 225
226 K T H T C P P C P A P E L L G G P S V F L F P P K 250
251 P K D T L M I S R T P E V T C V V V D V S H E D P 275
276 E V K F N W Y V D G V E V H N A K T K P R E E Q Y 300
301 N S T Y R V V S V L T V L H Q D W L N G K E Y K C 325
326 K V S N K A L P A P I E K T I S K A K G L Q P R E P 350
351 Q V Y T L L P P S R D E L L T K N Q V S L T C L V K G 375
376 F Y P S D I A V E W E S N G Q P E N N Y K T T P P 400
401 V L D S D G S F F L Y S K L T V D K S R W Q Q G N 425
426 V F S C S V M H E A L H N H Y T Q K S L S L S P G C
```

ETD HD 26%

(2 LC-MS runs combined)

```
N Q V Q L Q Q P G A E L V K P G A S V K M S C K A S 25
26 G Y T F T S Y N M H W V K Q T P G R G L E W I G A 50
51 I Y P G N G D T S Y N Q K F K G K A T L T A D K S 75
76 S S T A Y M Q L S S L T S E D S A V Y Y C A R I S T 100
101 Y Y G G D W Y F N V W G A G T T V T V S A A S T K 125
126 G P S V F P L A P S S K S T S G G T A A L G C L V 150
151 K D Y F P E P V T V S W N S G A L T S G V H T F P 175
176 A V L Q S S G L Y S L S S V V T V P S S L G T Q 200
201 T Y I C N V N H K P S N T K V D K K A E P K S C D 225
226 K T H T C P P C P A P E L L G G P S V F L F P P K 250
251 P K D T L M I S R T P E V T C V V V D V S H E D P 275
276 E V K F N W Y V D G V E V H N A K T K P R E E Q Y 300
301 N S T Y R V V S V L T V L H Q D W L N G K E Y K C 325
326 K V S N K A L P A P I E K T I S K A K G L Q P R E P 350
351 Q V Y T L L P P S R D E L L T K N Q V S L T C L V K G 375
376 F Y P S D I A V E W E S N G Q P E N N Y K T T P P 400
401 V L D S D G S F F L Y S K L T V D K S R W Q Q G N 425
426 V F S C S V M H E A L H N H Y T Q K S L S L S P G C
```

UVPD 30%

(single LC-MS run)

Unique Sequence Coverage

- LC-MS analysis of intact Rituximab
- ETD HD of the Heavy Chain provides up to 26% sequence coverage
- UVPD yields up to 30% sequence coverage
- UVPD provides more large fragments than ETD HD confirming the sequence in the middle
- Both ETD HD and UVPD combined provide up to 43% sequence coverage within 1 hour



UVPD Top-Down Of Intact IgG

Unique Sequence Coverage

- LC-MS analysis of intact Rituximab
- ETD HD of the Heavy Chain provides up to 26% sequence coverage
- UVPD yields up to 30% sequence coverage
- UVPD provides more large fragments than ETD HD confirming the sequence in the middle
- Both ETD HD and UVPD combined provide up to 43% sequence coverage within 1 hour

```
N Q V Q L Q Q P G A E L V K P G A S V K M S K A S 25
26 G Y T F T S Y N M H W V K Q T P G R G L E W I G A 50
51 I Y P G N G D T S Y N Q K F K G K A T L T A D K S 75
76 S S T A Y M Q L S S L T S E D S A V Y Y A R S T 100
101 Y Y G G D W Y F N V W G A G T T V T V S A A S T K 125
151 K D Y F P E P V T V S W N S G A L T S G V H T F P 175
176 A V L Q S S G L Y S L S S V V T V P S S S L G T Q 200
201 T Y I C N V N H K P S N T K V D K K A E P K S C D 225
226 K T H T C P P C P A P E L L G G P S V F L F P P K 250
251 P K D T L M I S R T P E V T C V V V D V S H E D P 275
276 E V K F N W Y V D G V E V H N A K T K P R E E Q Y 300
301 N S T Y R V V S V L T V L H Q D W L N G K E Y K C 325
351 Q V Y T L L P P S R D E L L T K N Q V S L T L V K G 375
376 F Y P S D I A V E W E S N G Q P E N N Y K T T P P 400
401 V L D S D G S F F L Y S K L T V D K S R W Q Q G N 425
426 V F S S V M H E A L H N H Y T Q K S L S L S P G C
```

ETD HD
26%

(2 LC-MS runs combined)

```
N Q V Q L Q Q P G A E L V K P G A S V K M S K A S 25
26 G Y T F T S Y N M H W V K Q T P G R G L E W I G A 50
51 I Y P G N G D T S Y N Q K F K G K A T L T A D K S 75
76 S S T A Y M Q L S S L T S E D S A V Y Y A R S T 100
151 K D Y F P E P V T V S W N S G A L T S G V H T F P 175
176 A V L Q S S G L Y S L S S V V T V P S S S L G T Q 200
201 T Y I C N V N H K P S N T K V D K K A E P K S C D 225
226 K T H T C P P C P A P E L L G G P S V F L F P P K 250
251 P K D T L M I S R T P E V T C V V V D V S H E D P 275
276 E V K F N W Y V D G V E V H N A K T K P R E E Q Y 300
301 N S T Y R V V S V L T V L H Q D W L N G K E Y K C 325
326 K V S N K A L P A P I E K T I S K A K G Q P R E P 350
351 Q V Y T L L P P S R D E L L T K N Q V S L T L V K G 375
376 F Y P S D I A V E W E S N G Q P E N N Y K T T P P 400
401 V L D S D G S F F L Y S K L T V D K S R W Q Q G N 425
426 V F S S V M H E A L H N H Y T Q K S L S L S P G C
```


UVPD
30%

(single LC-MS run)




UVPD Middle-Down Of Rituximab

ANTIBODY DIGESTION AND SEPARATION



HIGH RESOLUTION MS² SPECTRUM OF LIGHT CHAIN (LC)



Unique Sequence Coverage


- New UVPD fragmentation complements existing fragmentation techniques
- UVPD provides 20% unique sequence coverage vs. ETD/ETHcD
- Unambiguous glycosylation site localization and extensive coverage of the antigen-binding complementarity determining regions



UVPD Middle-Down Of Rituximab

Rituximab (Fc/2) total bond coverage by LC-MS middle-down

N G|P|S V|F|L|F|P P|K|P|K|D|T|L|M I|S|R|T P|E|V|T|C| 25
 26 V|V|V|D V|S|H|E|D|P|E|V|K|F|N|W|Y|V|D|G|V|E|V|H|N| 50
 51 A|K|T|K|P|R|E|E|Q|Y|N|S T Y R|V|V|S V L|T V L H Q 75
 76 D|W|L|N|G|K|E Y|K|C|K|V|S|N|K|A|L|P|A|P|I|E|K|T|I|100
 101|S|K|A|K|G|Q|P|R|E|P|Q V|Y T|L|P|P|S|R|D|E|L|T|K|N 125
 126|Q|V S L|T|C|L V|K G|F|Y|P|S|D|I|A|V|E|W|E|S|N|G|Q|150
 151|P|E|N|N|Y K|T T|P|P|V|L|D|S|D|G|S|F|F|L|Y|S|K|L|T 175
 176|V|D K|S|R|W|Q|Q|G|N|V|F|S|C|S|V|M H|E|A|L|H|N|H|Y 200
 201|T|Q|K|S|L S|L|S P|G C



	% Sequence coverage*	% Unique matched fragment		
		UVPD	ETD	EThcD
Fc/2	87	20	7	4
LC	80	21	12	5
Fd	72	19	18	4

(* Number of LC-MS/MS runs used: 3 ETD, 1 EThcD and 2 UVPD)

Rituximab Fc/2 (6 runs)





Unique Sequence Coverage

- New UVPD fragmentation complements existing fragmentation techniques
- UVPD provides 20% unique matched fragments vs. ETD/EThcD
- Unambiguous glycosylation site localization and extensive coverage of the antigen-binding complementarity determining regions




Middle-Down of NIST mAb: ETD and UVPD

Wide isolation window



Combining ETD and UVPD: All Runs



scFc – G0F

```

N G P[S V]F[L]F]P P]K]P]K]D]T]L]M]I]S]R]T]P]E]V]T]C 25
26]V]V]V]D]V]S]H]E]D]P]E]V]K]F]N]W]Y]V]D]G]V]E]V]H]N 50
51]A]K]T]K]P]R]E]E]Q]Y]N]S T Y]R]V]V]S]V]L]T]V]L]H]Q 75
76]D]W]L]N]G]K]E]Y]K]C]K]V]S]N]K]A]L]P]A]P]L]I]E]K]T]I 100
101]S]K]A]K]G]Q]P]R]E]P]Q]V]Y]T]L]P]P]S]R]E]E]M]T]K]N 125
126]Q]V]S]L]T]C]L]V]K]G]F]Y]P]S]D]I]A]V]E]W]E]S]N]G]Q 150
151]P]E]N]N]Y]K]T]T]P]P]V]L]D]S]D]G]S]F]F]L]Y]S]K]L]T 175
176]V]D]K]S]R]W]Q]Q]G]N]V]F]S]C]S]V]M]H]E]A]L]H]N]H]Y 200
201]T]Q]K]S]L]S]L]S]P]G]C
    
```

LC

```


N D]I]Q]M]T]Q]S]P]S]T]L]S]A]S]V]G]D]R]V]T]I]T]C]S]A 25
26]S]S]R]V]G]Y]M]H]W]Y]Q]K]K]P]G]K]A]P]K]L]L]I]Y]D]T 50
51]S]K]L]A]S]G]V]P]S]R]F]S]G]S]G]S]G]T]E]F]T]L]T]I]S 75
76]S]L]Q]P]D]D]F]A]T]Y]Y]C]F]Q]G]S]G]Y]P]F]T]F]G]G]G 100
101]T]K]V]E]I]K]R]T]V]A]A]P]S]V]F]I]F]P]P]S]D]E]Q]L]K 125
126]S]G]T]A]S]V]V]C]L]L]N]N]F]Y]P]R]E]A]K]V]Q]W]K]V]D 150
151]N]A]L]Q]S]G]N]S]Q]E]S]V]T]E]Q]D]S]K]D]S]T]Y]S]L]S 175
176]S]T]L]L]T]L]S]K]A]D]Y]E]K]H]K]V]Y]A]C]E]V]T]H]Q]G]L 200
201]S]S]P]V]T]K]S]F]N]R]G]E]C]C
    
```

Fd

```

N Q]V]T]L]R]E]S]G]P]A]L]V]K]P]T]Q]T]L]T]L]T]C]T]F]S 25
26]G]F]S]L]S]T]A]G]M]S]V]G]W]I]R]Q]P]P]G]K]A]L]E]W]L 50
51]A]D]I]W]W]D]D]K]K]H]Y]N]P]S]L]K]D]R]L]T]I]S]K]D]T 75
76]S]K]N]Q]V]V]L]K]V]T]N]M]D]P]A]D]T]A]T]Y]Y]C]A]R]D 100
101]M]I]F]N]F]Y]F]D]V]W]G]Q]G]T]T]V]T]V]S]S]A]S]T]K]G 125
126]P]S]V]F]P]L]A]P]S]S]K]S]T]S]G]G]T]A]A]L]G]C]L]V]K 150
151]D]Y]F]P]E]P]V]T]V]S]W]N]S]G]A]L]T]S]G]V]H]T]F]P]A 175
176]V]L]Q]S]S]G]L]Y]S]L]S]S]V]V]T]V]P]S]S]S]L]G]T]Q]T 200
201]Y]I]C]N]V]N]H]K]P]S]N]T]K]V]D]K]R]V]E]P]K]S]C]D]K 225
226]T]H]T]C]P]P]C]P]A]P]E]L]L]G]C
    
```

Combining ETD and UVPD: Only Two Runs



Even with only 2 runs: the combination of ETD and UVPD gives more sequence coverage

Thermo Scientific BioPharma Finder 3.0 Software Preview (End of 2017)

Experiment Types


Protein Sequence Manager >

Peptide Mapping Analysis >

Intact Protein Analysis >

Top Down Analysis >

(Time defined data processing)




Example Applications Of UVPD



Comprehensive sequence
characterization/confirmation of
protein drugs



Identification and characterization of
intact proteins by MS



Thermo Scientific™ Orbitrap Fusion™ Lumos™ MS with UVPD provides a unique fragmentation mode for unmatched large and small molecule structure determination for Proteomics, Metabolomics, and Biopharma applications.



Northwestern
University



“

UVPD is unique because of the different fragmentation channels and there are so many of them which leads to complete molecular characterization for proteins and proteoforms. The depth of analysis afforded by UVPD, combined with the speed of the OT Fusion Lumos and proper software is very impressive.

”



“

The Orbitrap Fusion Lumos with UVPD allows us to more comprehensively characterize complex mixtures of lipids that are present in a given biological sample, in order to understand their functional roles in the progression of disease.

Gavin Reid, The University Of Melbourne

”

To know more, please watch recorded webinar on c&en WEBINARS website:

https://cen.acs.org/media/webinar/thermo_090717.html

c&en | WEBINARS

Let's Chew the Fat with Orbitrap MS - Enabling Lipid Metabolic Flux Studies and Structural Elucidation of Lipids with Ultra High Resolution and UVPD Fragmentation

planetorbitrap.com/orbitrap-fusion-lumos

thermofisher.com/Lumos

Acknowledgements

Thermo Scientific

Graeme McAlister	Shannon Eliuk	Rich Klein
Jesse Canterbury	Eugen Damoc	Rick Carberry
Phil Remes	August Specht	Martin Zeller
Chris Mullen	Andreas Huhmer	Alexander Harder
Mike Senko	Jonathan Joseph	Howard Tran
Mark Hardman	Alexander Makarov	Evet Kruka
Derek Bailey	Edward Denisov	Randy Porch
Andreas Wieghaus	Reiko Kiyonami	Maroun El Khoury
Rosa Viner	Terry Zhang	Paul Fayad
Tim Stratton	Iain Mylchreest	Sarah Horsley
Kate Comstock	Ken Miller	Wilfried Voorhorst
Thomas Moehring	Daniel Lopez-Ferrer	Jocelyn Dupuy
Romain Huguet	Christian Thoeing	Peter Suemmchen
Stephane Houel	Jack Cunniff	Willy Bjorklund
Helen Cardasis	Kevin Wheeler	Daniel Grenno
Seema Sharma	John Butler	Tran Howard
Michael Blank	Willi Bjorklund	Uma Kota
Ed Gonzalez	Tony Ziberna	
Haichuan Liu		

Collaborators

Luca Fornelli and Kristina Srzentić (Kelleher's lab)
Dustin D Holden (Brodbelt's lab)
Gavin Reid
Catherine Going (Pitteri's lab)
Evgeniy Petrotchenko and Nick Brodie (Borchers' lab)
Peter Verhaert (ProteoFormiX)
Mónica Carrera (CSIC Marine Institute Spain)
Mark Berhow (USDA Illinois)
Alex Herbert (Coon's lab)
Matthew Mitsche (UT Southwestern Medical Center)
Jeff Gilbert (DOW AgroSciences LLC)
Ron Aoyama (Gilead Sciences)
Joanna Szpunar (IPREM, Universite De Pau, France)
Facundo Fernandez, Georgia tech
Chad Weisbrod (National Magnet Lab, FL)

